Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1415-1425

  Patterson, Dan M ^a   Zweifel, Martin ^a   Middleton, Mark R ^b   Price, Patricia M ^d   Folkes, Lisa K ^c   Stratford, Michael R L ^c   Ross, Phil ^e   Halford, Sarah ^e   Peters, Jane ^e   Balkissoon, Jai ^f   Chaplin, Dai J ^f   Padhani, Anwar R ^a   Rustin, Gordon J S ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Academic Department of Radiation Oncology   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f OXiGENE Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; COMBRETASTATIN A1 PHOSPHATE; DEXAMETHASONE; GLYCERYL TRINITRATE; METOCLOPRAMIDE; MORPHINE; ONDANSETRON; PARACETAMOL; PROPRANOLOL; VASCULAR TARGETING AGENT;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASYMPTOMATIC DISEASE; ATAXIA; BACKACHE; BLADDER OBSTRUCTION; BLADDER SPASM; BLOOD TOXICITY; BLURRED VISION; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PAIN; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CARCINOMA; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM FISTULA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIUM CARCINOMA; EPITHELIUM TUMOR; FATIGUE; FEMALE; FEVER; FLANK PAIN; FLU LIKE SYNDROME; HEADACHE; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIP CARCINOMA; LIVER FAILURE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEUROPATHY; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS ADENOCARCINOMA; PERITONITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; QT PROLONGATION; RIGOR; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TESTIS TERATOMA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TOOTH PAIN; TREATMENT DURATION; TUMOR BLOOD FLOW; TUMOR LYSIS SYNDROME; UNSTEADINESS; UTERUS MYOMA; UVEA MELANOMA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DIPHOSPHATES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; STILBENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857692454     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2414     Document Type: Article

References (32)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
2. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005;115:2992-3006. (Pubitemid 41567565)
3. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000. (Pubitemid 34224587)
4. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300. (Pubitemid 26242979)
5. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003;23:1433-40. (Pubitemid 36754111)
6. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW III, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004;10:1446-53. (Pubitemid 38365240)
7. Folkes LK, Christlieb M, Madej E, Stratford MR, Wardman P. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 2007;20:1885-94.
8. Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert LWIII, Martin SW, et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res 2002;22:3933-40. (Pubitemid 36134416)
9. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47. (Pubitemid 27337928)
10. Stratford MR, Folkes LK. Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2673-6.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. d'Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO. Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics 2006;26:621-32. (Pubitemid 43515329)
13. Galbraith S, Lodge M, Taylor N, Rustin G, Bentzen S, Stirling J, et al. Reproducibility of dynamic contrast enhanced MRI in human muscle and tumours - comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-42. (Pubitemid 34213403)
14. Hunter GJ, Hamberg LM, Choi N, Jain RK, McCloud T, Fischman AJ. Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: correlating vascular physiology with glucose metabolism. Clin Cancer Res 1998;4:949-55. (Pubitemid 28183396)
15. Padhani A, Gapinski C, Macvicar D, Parker G, Suckling J, Revell P, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109. (Pubitemid 32054531)
16. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42. (Pubitemid 46621830)
17. Hill SA, Tozer GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002;22:1453-8. (Pubitemid 34839149)
18. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22. (Pubitemid 46621828)
19. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a singledose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16. (Pubitemid 34651387)
20. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-44. (Pubitemid 37363426)
21. Patterson DM, Rustin GJS. Vascular damaging agents. Clin Oncol 2007;19:443-56. (Pubitemid 46995617)
22. Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 2010;16:5892-9.
23. Rischin D, Bibby DC, Chong G, Kremmidiotis G, Leske AF, Matthews CA, et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res 2011;17:5152-60.
24. Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2010;37 Suppl 1:S164-82.
25. Evelhoch JL, LoRusso PM, He Z, Del Proposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7. (Pubitemid 38697598)
26. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159-67.
27. Price PM, Asselin M, Koetz B, Dickinson C, Charnley N, Lorigan P, et al. A PET imaging study of the vascular disruptive agent OXi4503 to confirm in vivo mechanism of action in a phase I trial. J Clin Oncol 27, 2009 (suppl; abstr e14510).
28. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 2009;69:7524-8.
29. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7. (Pubitemid 44454154)
30. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
31. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-31.
32. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32-7.